P

Prilenia

Develops pridopidine treatments for neurodegenerative diseases

Vice President, Data Management - Chief Data Scientist

Full-Time
No salary listed
Expert
Bachelor's
Remote in USA+1 moreMore locations: Boston, MA, USA
RemoteFlexible schedule across North America, Europe, and Israel time zones; travel up to 15%, including CRO and site visits, investigator meetings, and regulatory interactions.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • An advanced degree in life sciences, health informatics, statistics, computer science, or a related field is preferred.
  • At least 12 years of progressive clinical data management experience in the pharmaceutical, biotechnology, or CRO industry, including at least five years in a senior leadership role.
  • Direct experience leading data management through at least one successful NDA, BLA, or MAA submission, including database lock and submission data package delivery.
  • Deep working knowledge of CDISC standards (CDASH, SDTM, ADaM) and experience ensuring submission-ready datasets.
  • Hands-on experience with major EDC/CDMS platforms such as Medidata Rave, Veeva Vault CDMS, or Oracle InForm/Clinical One.
  • Strong knowledge of FDA regulations, ICH-GCP, and 21 CFR Part 11 as applied to clinical data management.
  • Demonstrated success managing CROs and data management vendors, including budget and timeline accountability.
  • Experience supporting or leading through an FDA pre-approval inspection or comparable regulatory audit.
  • Experience in a small or mid-size clinical-stage biotech environment, including building a data management function and direct experience in US marketing authorization submission.
  • Experience in a therapeutic area relevant to Prilenia’s pipeline, such as neurology, rare disease, or CNS.
  • Experience with risk-based quality management (RBQM) and centralized statistical monitoring approaches.
  • Knowledge of regulatory frameworks and requirements for data management, including FDA and EMA requirements.
  • Familiarity with real-world data sources, patient registries, or external control arms.
  • Familiarity with the evolving role of AI and computational science in clinical and regulatory activities.
  • Ability to work independently and collaboratively in a team environment.
  • Ability to meet deadlines and work under pressure.
  • Flexibility to adapt to changing priorities and tasks.
  • Ability to work effectively in a global collaborative team environment.
Responsibilities
  • Serve as the senior data management leader and subject matter expert for all data management, supporting preparations for global marketing authorization applications.
  • Collaborate with the Chief Data Protection Officer to ensure data integrity and compliance globally.
  • Develop and execute the clinical data management strategy across ongoing and planned trials, aligned with regulatory timelines and submission milestones.
  • Own end-to-end database lock planning and execution for pivotal trials, ensuring on-time, audit-ready locks that support statistical analysis and NDA filing timelines.
  • Represent data management in FDA interactions, including Type B/C meetings and briefing document preparation, and other relevant meetings with regulatory authorities; respond to information requests during regulatory review.
  • Partner with Regulatory Affairs and Biostatistics to ensure the submission data package (SDTM, ADaM, define.xml, and reviewer’s guides) meets FDA Technical Rejection Criteria, current CDISC standards, and other relevant regulations.
  • Oversee development of Data Management Plans, CRF/eCRF design, edit check specifications, and data validation plans for all studies.
  • Ensure timely, high-quality data cleaning, query management, SAE reconciliation, and coding (MedDRA, WHO-DD) across active protocols.
  • Establish and monitor data quality metrics, including query rates, query aging, data entry lag, and protocol deviations affecting data, and drive continuous improvement.
  • Oversee external data reconciliation for central lab, ECG, imaging, ePRO/eCOA, and IRT/IWRS data, as well as third-party data integration.
  • Ensure company-wide adherence to CDISC standards (CDASH, SDTM, ADaM) and maintain standards governance across studies and vendors.
  • Partner with IT and relevant functions to ensure systems and processes comply with 21 CFR Part 11, GDPR/HIPAA as applicable, and company data privacy and information security policies.
  • Manage relationships with data management CROs, EDC vendors, and specialty data vendors, including scope, budget, timelines, and quality oversight through service level agreements and metrics.
  • Lead vendor selection, including RFP processes and bid defenses, for data management services and systems as the portfolio scales.
  • In collaboration with Quality, conduct or oversee relevant vendor audits and ensure timely resolution of findings related to data management deliverables.
  • Ensure data management practices comply with ICH-GCP, FDA regulations, and company SOPs, and maintain inspection-ready documentation, including Trial Master File data management sections, audit trails, and data management plans.
  • Lead data management readiness for regulatory authorities, including FDA pre-approval inspections and sponsor audits, through mock inspections and CAPA management.
  • Review and maintain data management SOPs, working practices, and training materials; ensure staff and vendor training compliance.
  • Manage a hybrid internal/outsourced model appropriate to the company's current size and stage.
  • Partner with Biostatistics and Statistical Programming on analysis-ready data timelines, and with Clinical Operations on site-level data quality and monitoring plans.
  • Manage the data management function’s budget, resourcing, and vendor spend; report progress and risks to senior leadership and, as appropriate, the Board.
  • Contribute as a data management subject matter expert in cross-functional, alliance management, and business development activities as required.
Desired Qualifications
  • Excellent written and verbal communication skills, including experience presenting to senior leadership and interacting with regulatory agencies.
  • Strong analytical and problem-solving abilities.
  • Strong attention to detail.
  • Highly organized and self-motivated.
  • Strong interpersonal skills and the ability to build relationships.

About the company

Prilenia develops and commercializes medicines for brain diseases. It focuses on creating treatments for neurodegenerative conditions (like Huntington’s disease and ALS) and neurodevelopmental disorders. Its main candidate is pridopidine, a drug studied to help brain cells by activating the sigma-1 receptor (S1R), which researchers believe can help restore brain pathways impaired in these diseases. The product works by engaging S1R to support neuronal function, with the goal of slowing symptoms or progression once approved. Prilenia aims to stand out by its specific focus on S1R biology, building a pipeline of potential therapies, and bringing these treatments to patients through regulatory approval and commercialization. The company’s goal is to provide validated therapies that address urgent needs for patients and families affected by neurodegenerative and neurodevelopmental disorders, while growing its team and expanding its pipeline for future medicines.

Company Size

51-200

Company Stage

Series B

Total Funding

$115.5M

Headquarters

Herzliya, Israel

Founded

2018

Get referred to Prilenia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PRECISE-HD began July 7, 2026, restoring a path toward Huntington's disease approval.
  • PREVAiLS enrolled its first ALS participant on March 30, 2026, expanding the pipeline.
  • Prilenia appointed Elisabeth Leiderman in April 2026 to manage Phase 3 financing runway.

What critics are saying

  • EMA refused Nurzigma in July 2025, then Prilenia withdrew the filing in November 2025.
  • PRECISE-HD and PREVAiLS still depend on one molecule, pridopidine, for company survival.
  • Any Phase 3 failure in HD or ALS leaves Prilenia without a second clinical asset.

What makes Prilenia unique

  • Pridopidine targets sigma-1 receptor biology across Huntington's disease and ALS programs.
  • Ferrer co-develops and commercializes pridopidine across Europe, MENA, Africa, and Latin America.
  • Prilenia still runs dual Phase 3 programs, unusually broad for a single-asset biotech.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Wellness Program
  • Mental Health Support
  • Conference Attendance Budget
  • Family Planning Benefits
  • Fertility Treatment Support
  • Stock Options
  • 401(k) Retirement Plan
  • 401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

5%
Contract Pharma
Sep 8th, 2026
Prilenia taps Rick Munschauer as new Chief Medical Officer.

Prilenia taps Rick Munschauer as new Chief Medical Officer. Munschauer has been CMO at three previous biopharmaceutical companies, most recently Emalex Biosciences. September 8, 2026 Content Marketing Editor Why This Matters: See our coverage of other industry executive team appointments and promotions here. Prilenia Therapeutics announced the appointment of Frederick (Rick) E. Munschauer III, MD, as its new Chief Medical Officer (CMO). New Chief Medical Officer bona fides. Munschauer joins after having been CMO at three previous biopharmaceutical companies, most recently Emalex Biosciences. He also held the post at MedDay Pharmaceuticals and Marathon Pharmaceuticals. Other previous work experience includes Biogen and EMD Serono, in addition to an extensive academic career. "Prilenia is currently tackling two devastatingly intractable diseases, in HD and ALS, where the unmet need is stark, and where we now have a possibility of changing the course of illness." Rick Munschauer, Prilenia Therapeutics CMO Prilenia's focus, meanwhile, is accelerating scientific progress to help those affected by Huntingdon's disease (HD) and amyotrophic lateral sclerosis (ALS). "Prilenia is currently tackling two devastatingly intractable diseases, in HD and ALS, where the unmet need is stark," Munschauer said. "We now have a possibility of changing the course of illness. What drew me here is the clarity of the mission and the pridopidine story, which has already garnered compelling data. My focus will be on execution - running our pivotal HD and ALS studies to the highest standard." Prilenia moving trials forward. In July 2026, Prilenia and Ferrer announced initiation of a confirmatory study of pridopidine in Huntingdon's disease. Munschauer has been principal or co-principal investigator for over 50 Phase I-IV trials in multiple sclerosis and cerebrovascular disease. He has authored more than 90 peer-reviewed publications. Other conditions Munschauer has worked on include pediatric Tourette syndrome and Duchenne muscular dystrophy. All of that makes for an impressive resume, says Prilenia CEO Michael Hayden, PhD. Munschauer's experience is especially important, explains Hayden, as Prilenia executes Phase III studies in both HD and ALS. "That combination of clinical judgment, regulatory experience and operational discipline will bring significant value to Prilenia, and patients," Hayden said.

Associated Press
Apr 28th, 2026
Prilenia names Dr. Elisabeth Leiderman as CFO to lead financial strategy through Phase 3 trials

Prilenia Therapeutics, a biopharmaceutical company focused on Huntington's disease and Amyotrophic Lateral Sclerosis treatments, has appointed Dr Elisabeth Leiderman as Chief Financial Officer. Leiderman brings over 20 years of finance and corporate development experience in life sciences. She has previously served as CFO at multiple biotech companies including Dewpoint, Atsena and Decibel, and currently sits on the board of Autolus Therapeutics. She also held senior investment banking positions at UBS, Credit Suisse and Nomura. The appointment comes as Prilenia embarks on two Phase 3 studies for its drug pridopidine in HD and ALS. Leiderman will focus on managing the company's financial runway through Phase 3 completion whilst preparing for potential commercialisation.

AIJourn
Apr 28th, 2025
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets

NAARDEN, Netherlands & WALTHAM, Mass. - (BUSINESS WIRE) - Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets.

BioSpace
Sep 19th, 2024
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer

Prilenia appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer.

Business Wire
Apr 12th, 2024
Prilenia To Present Latest Research From Its Pridopidine Programs For Huntington Disease And Als At Aan 2024

NAARDEN, Netherlands WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, today announced the presentation of the latest research from the pridopidine Huntington disease (HD) and amyotrophic lateral sclerosis (ALS) programs at the American Academy of Neurology (AAN) Annual Congress, in Denver, Colorado, April 13-18. “Pridopidine is now in pre-registration phase in HD, with a first submission planned Mid 2024i, and is also set to commence a global Phase 3 study in ALS later this year. We are making significant strides forward and this is reflected by presentation of the data at one of the most important medical congresses in the field of Neurology,” said Jina Swarz, MD. Ph.D., the recently appointed Chief Medical Officer of Prilenia. “Pridopidine is one of the most advanced investigational new drugs in HD and ALS and has shown consistent treatment benefits across independent measures that are important to patients and families. The presented data advances knowledge in the field, providing important learnings for both clinical practice and for the design of our programs going forward